CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS)
Jackson T. Bowers(University of California, San Francisco), Michael A. Spinner(Stanford Medicine), Michael P. Randall(Dartmouth College), Mwanasha H. Merrill(Dana-Farber Cancer Institute), Weiyun Z. Ai(City College of San Francisco), Karthik A. Ganapathi(University of California, San Francisco), James L. Rubenstein(UCSF Helen Diller Family Comprehensive Cancer Center), Charalambos Andreadis(University of California, San Francisco), Sonam Prakash(University of California, San Francisco), Carrie Ho(University of California, San Francisco), LD Kaplan(University of California, San Francisco), Natalie Gill(Gladstone Institutes), Reuben Thomas(Gladstone Institutes), Michela Traglia(Gladstone Institutes), W. Patrick Devine(University of California, San Francisco), Madhav R. Seshadri(University of California, San Francisco), Anjanaa Vijayanarayanan(University of California, San Francisco)
Cited by 0
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487